Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 21,977 results that match your search.21,977 results
  • The United Arab Emirates recently signed a Trade and Investment Framework Agreement with the United States. The purpose of the agreement is to develop ways for both countries to expand their bilateral trade and investment relationship. The value of trade between the US and the UAE was reported to be in the vicinity of $4.6 billion in the year 2003 and with an open market and a large economy, the Free Trade Agreement (FTA) should bring more investment into the country and this figure could grow exponentially. A good example of how much open markets can do is the success that the various free zones established in the UAE have had. The FTA will also enhance the technology base here. But what does this mean for companies coming into the UAE?
  • On June 21 2005, the Secretary of Health issued Administrative Order Number 2005-0016, entitled General Policies and Guidelines Governing Brand Names of Products for Registration with the Bureau of Food and Drugs (BFAD). BFAD officials are thought to believe that IP issues relating to brand names have impeded their ability to implement effectively the misbranding provisions of Republic Act 3720, known as the Food, Drugs and Devices and Cosmetics Act. The most important features of the new Order are:
  • Emma Barraclough, Hong Kong
  • Enquiries into alleged corruption in Hong Kong have cast light on the hidden role of IP investigators in the fight against counterfeiting. Emma Barraclough reports
  • Sam Mamudi, New York
  • On July 13 2005, the English Court of Appeal handed down its judgment in the British Horseracing Board (BHB) v William Hill case. The decision ended a dispute that started in the High Court about five years ago and has involved two trips to the Court of Appeal and one to the European Court of Justice (ECJ).
  • MIP's latest survey of the largest IP practices in Asia, Europe and the US shows how a growing trend towards consolidation is re-shaping IP practices in many parts of the world
  • Two recent cases in the still blurred area of market dominance have left pharmaceutical companies holding their breath. Sophie Lawrance and Pat Treacy examine the cases and whether the way in which competition law is enforced is becoming an obstacle to the pharmaceutical industry's success